Scholar Progress Reports
Taubman Scholars are required to submit an annual report on the progress of the research funded by their Taubman Institute grant. These progress reports are due on the anniversary of the effective date of the grant. For most Taubman Scholars and Senior Scholars, that would be July 1; however, for some Emerging Scholars and Taubman Scholars, the effective date of the grant could be different. We encourage Scholars to check their letter of appointment to confirm the effective date.
As the letter of appointment states, the annual report should set forth the research plan, progress on the plan, any findings to date, any publications based on this research, any issues, and any other relevant material. As the NIH suggests, the report should be written in language understandable to a biomedical scientist who may not be a specialist in the project's research field. Abbreviations and language that may not be known to the broader scientific community should be avoided unless clearly defined.
These progress reports will be submitted to the Taubman Institute’s Scientific Advisory Board for review, as well as distributed to the organization’s Governing Council. They will be also used to facilitate the Taubman Institute’s communications, community outreach and public engagement efforts.
To simplify the task and to ensure consistency, the Taubman Institute asks that Scholars use Progress Report form below for all submissions.
Progress Report Form
Taubman-sponsored research offers breast tumor insights
Taubman Emerging Scholar Dr. Scott Tomlins has authored a new study about phyllodes tumors.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
Familial ALS affects generations
Detroit News column featuring Dr. Eva Feldman depicts the toll of the disease on one Metro Detroit family
news & events
In the News
Taubman Emerging Scholar makes strides against cancer
Erika Newman, M.D., has identified a characteristic of deadly childhood neuroblastoma that may pave the way for more effective treatments.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.